Bristol Activities of Daily Living (BADLS) for Dementia
Carer-rated ADL scale for dementia patients assessing 20 daily activities. Score 0-60; higher scores indicate greater dependency. Used in acetylcholinesterase inhibitor monitoring.
Score interpretation
→ Continue current support; community care; memory clinic follow-up; reassess in 6 months; encourage independence
→ OT home assessment; carers assessment; assistive technology; review acetylcholinesterase inhibitor response; social services referral
→ Care home assessment likely; 24h care needs; safeguarding; carer burnout assessment; consider memantine for severe dementia; palliative approach planning
Interpretation bands for the Bristol ADL Scale. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Exenatide · GLP-1 Receptor Agonist
- Donepezil · Acetylcholinesterase inhibitor (AChEI) — dementia
- Memantine · NMDA receptor antagonist — dementia
- Rivastigmine · Dual AChEI and BuChEI inhibitor — dementia
- Quetiapine (Elderly — Dementia Caution) · Atypical Antipsychotic
- Memantine · NMDA Receptor Antagonist — Dementia
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.